3001 - 3010 of 9118 Results
Title
Year
-
OPENTitle: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 25End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012Best OA location URL: http://www.prd-journal.com/article/S1353802021001450/pdfCitation Count: 22
- Plasma NfL, clinical subtypes and motor progression in Parkinson's disease2021OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Citation Count: 60
- Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease2021RESTRICTEDTitle: Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 111End Page: 118Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.05.005Citation Count: 15
- Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach2021RESTRICTEDTitle: Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approachJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 124End Page: 129Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.05.011Citation Count: 20
- Coincident parkinsonism and myasthenia gravis: A case series2021RESTRICTEDTitle: Coincident parkinsonism and myasthenia gravis: A case seriesJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 89Issue #:Start Page: 4End Page: 5Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.06.016Citation Count: 10
- Telemedicine and Deep brain stimulation - Current practices and recommendations2021RESTRICTEDTitle: Telemedicine and Deep brain stimulation - Current practices and recommendationsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 89Issue #:Start Page: 199End Page: 205Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.07.001Citation Count: 27
- Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease2021RESTRICTEDTitle: Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 90Issue #:Start Page: 27End Page: 32Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.07.024Citation Count: 24
- A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic „CERAD-Plus“ tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study2021RESTRICTEDTitle: A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic „CERAD-Plus“ tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 90Issue #:Start Page: 90End Page: 97Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.07.034Citation Count: 15
- Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease2021RESTRICTEDTitle: Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 186Issue #:Start Page: 108465End Page: 108465Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108465Citation Count: 19
-
OPENTitle: Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonistJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 196Issue #:Start Page: 108693End Page: 108693Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108693Best OA location URL: https://hdl.handle.net/11584/325357Citation Count: 26